FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

被引：0
|
作者：
Lacombe, C. [1 ]
Perrier, M. [2 ]
Hentic, O. [1 ]
Brixi, H. [2 ]
Rebours, V [1 ]
Cadiot, G. [2 ]
Ruszniewski, P. [1 ]
de Mestier, L. [1 ]
机构：
[1] Univ Paris, Beaujon Hosp, APHP Nord, Dept Gastroenterol Pancreatol, Clichy, France
[2] Univ Reims, Robert Debre Hosp, Dept Hepatogastroenterol & Digest Oncol, Reims, France
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
neuroendocrine tumor; antiangiogenic therapy; vegf; well-differentiated;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I17
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [41] Identification of Primary Tumors in Patients Presenting With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
    Keck, Kendall
    Maxwell, Jessica
    Menda, Yusuf
    Bellizzi, Andrew
    Dillon, Joseph
    O'Dorisio, Thomas
    Howe, James
    PANCREAS, 2017, 46 (03) : 441 - 442
  • [42] SURVIVORSHIP CARE MODEL FOR PATIENTS WITH METASTATIC NEUROENDOCRINE TUMORS
    Laffan, Angela
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [43] A PHASE I STUDY OF AXITINIB (AG-013736) PLUS FOLFOX CHEMOTHERAPY AND BEVACIZUMAB IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Abhyankar, V. V.
    Sharma, S.
    Trowbridge, R. C.
    Robles, R. L.
    Tarazi, J.
    Kim, S.
    Tortorici, M.
    Hee, B.
    Burgess, R. E.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [44] Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors
    Keck, Kendall J.
    Maxwell, Jessica E.
    Menda, Yusuf
    Bellizzi, Andrew
    Dillon, Joseph
    O'Dorisio, Thomas M.
    Howe, James R.
    SURGERY, 2017, 161 (01) : 272 - 278
  • [45] Serum and Ascites Chromogranin A in Patients with Metastatic Neuroendocrine Tumors
    Warner, R.
    Curran, T.
    Shafir, M.
    Schiano, T.
    Khaitova, V
    Kim, M. K.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 141 - 142
  • [46] Survivorship Care Model for Patients with Metastatic Neuroendocrine Tumors
    Laffan, A.
    NEUROENDOCRINOLOGY, 2020, 110 : 89 - 89
  • [47] Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
    Yang, Meiling
    Yang, Ciqiu
    Ma, Dong
    Li, Zijun
    Zhao, Wei
    Yang, Dongyang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [48] Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
    Alfredo Berruti
    Nicola Fazio
    Anna Ferrero
    Maria Pia Brizzi
    Marco Volante
    Elisabetta Nobili
    Lucia Tozzi
    Lisa Bodei
    Mirella Torta
    Antonio D’Avolio
    Adriano Massimiliano Priola
    Nadia Birocco
    Vito Amoroso
    Guido Biasco
    Mauro Papotti
    Luigi Dogliotti
    BMC Cancer, 14
  • [49] Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
    Berruti, Alfredo
    Fazio, Nicola
    Ferrero, Anna
    Brizzi, Maria Pia
    Volante, Marco
    Nobili, Elisabetta
    Tozzi, Lucia
    Bodei, Lisa
    Torta, Mirella
    D'Avolio, Antonio
    Priola, Adriano Massimiliano
    Birocco, Nadia
    Amoroso, Vito
    Biasco, Guido
    Papotti, Mauro
    Dogliotti, Luigi
    BMC CANCER, 2014, 14
  • [50] Metastatic urachal cancer responding to FOLFOX chemotherapy
    Tran, Ben
    McKendrick, Joe
    CANADIAN JOURNAL OF UROLOGY, 2010, 17 (02) : 5120 - 5123
12345